LACEWING: Phase III Study of Gilteritinib + Azacitidine vs Azacitidine for Patients With Newly Diagnosed FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
Phase III study results show significantly higher composite complete remission rates but similar overall survival with gilteritinib + azacitidine vs azacitidine alone in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 177 KB
Released: December 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings